MDWD - רווח למניה בשנים עשר החודשים האחרונים MediWound Ltd
MediWound Ltd. generates revenue from the sale of enzyme-based treatments for chronic ulcers and burns. While production is outsourced to external partners, the unique purification method remains an internal asset. Its status as a biopharmaceutical innovator is underscored by investments in tissue regeneration. The rolling annual earnings per share chart visualizes equity income, where the -1.82 metric reflects the current dynamics of the business's fundamental strength.
פילוחי מדדים ואנליטיקה של חברת mediwound.com (MDWD)
The integration of the NexoBrid enzymatic drug into emergency medicine directly impacts the financial stability of MediWound Ltd. (MDWD), transforming a technological advantage into actual cash flow. This chart of the 12-month net income per share reflects the company's total earnings distributed across the entire share issuance, allowing investors to assess business efficiency without accounting for capital dilution.
